International Stem Cell Corporation

OTCPK:ISCO Stock Report

Market Cap: US$2.9m

International Stem Cell Management

Management criteria checks 3/4

International Stem Cell's CEO is Andrey Semechkin, appointed in Nov 2009, has a tenure of 16.83 years. total yearly compensation is $88.54K, comprised of 77.4% salary and 22.6% bonuses, including company stock and options. directly owns 51.07% of the company’s shares, worth $1.47M. The average tenure of the management team and the board of directors is 13.3 years and 18.5 years respectively.

Key information

Andrey Semechkin

Chief executive officer

US$88.5k

Total compensation

CEO salary percentage77.41%
CEO tenure16.8yrs
CEO ownership51.1%
Management average tenure13.3yrs
Board average tenure18.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Andrey Semechkin's remuneration changed compared to International Stem Cell's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$582k

Mar 31 2026n/an/a

-US$382k

Dec 31 2025US$89kUS$69k

-US$418k

Sep 30 2025n/an/a

-US$59k

Jun 30 2025n/an/a

-US$241k

Mar 31 2025n/an/a

-US$251k

Dec 31 2024US$66kUS$66k

-US$209k

Sep 30 2024n/an/a

-US$523k

Jun 30 2024n/an/a

-US$467k

Mar 31 2024n/an/a

-US$311k

Dec 31 2023US$113kUS$67k

-US$131k

Sep 30 2023n/an/a

US$195k

Jun 30 2023n/an/a

-US$79k

Mar 31 2023n/an/a

-US$356k

Dec 31 2022US$396kUS$63k

-US$331k

Sep 30 2022n/an/a

-US$705k

Jun 30 2022n/an/a

-US$527k

Mar 31 2022n/an/a

-US$309k

Dec 31 2021US$126kUS$58k

-US$899k

Sep 30 2021n/an/a

-US$1m

Jun 30 2021n/an/a

-US$2m

Mar 31 2021n/an/a

-US$3m

Dec 31 2020US$54kUS$54k

-US$3m

Sep 30 2020n/an/a

-US$5m

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

-US$4m

Dec 31 2019US$201kUS$44k

-US$4m

Compensation vs Market: Andrey's total compensation ($USD88.54K) is below average for companies of similar size in the US market ($USD650.37K).

Compensation vs Earnings: Andrey's compensation has increased whilst the company is unprofitable.

CEO

Andrey Semechkin (66 yo)

16.8yrs
Tenure
US$88,544
Compensation

Prof. Dr. Andrey Semechkin, Ph D., has been the Chief Executive Officer of International Stem Cell Corporation since November 15, 2009 and has been its Co-Chairman of the Board since October 6, 2011 and ha...

Leadership Team

NamePositionTenureCompensationOwnership
Andrey Semechkin
Co-Chairman of the Board & CEO16.8yrsUS$88.54k51.07%
$ 1.5m
Russell Kern
Executive VP13.3yrsUS$370.00k0%
$ 0
Rebecca McGee
President of Lifeline Cell Technology4.7yrsno datano data
13.3yrs
Average Tenure

Experienced Management: ISCO's management team is seasoned and experienced (13.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andrey Semechkin
Co-Chairman of the Board & CEO17.8yrsUS$88.54k51.07%
$ 1.5m
Russell Kern
Executive VP17.9yrsUS$370.00k0%
$ 0
Paul Maier
Independent Director19.2yrsUS$94.80k0.41%
$ 11.8k
Mark Hughes
Member of Scientific Advisory Boardno datano datano data
Donald Wright
Independent Co-Chairman of the Board19.5yrsUS$109.80k0.059%
$ 1.7k
Evan Snyder
Member of Scientific Advisory Boardno datano datano data
Elena Revazova
Member of Scientific Advisory Boardno datano datano data
Hans-Dieter Volk
Member of Scientific Advisory Boardno datano datano data
Matthias von Herrath
Member of Scientific Advisory Boardno datano datano data
Michael Kalichman
Member of Scientific Advisory Boardno datano datano data
Rosario Sánchez-Pernaute
Member of Scientific Advisory Boardno datano datano data
18.5yrs
Average Tenure
70yo
Average Age

Experienced Board: ISCO's board of directors are seasoned and experienced ( 18.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 08:11
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

International Stem Cell Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBrookline Capital Markets
Maxim JacobsEdison Investment Research